RE: First Patient Treated Keytruda Int-23061 Nov 2019 07:07
For your benefit O'Donnell
Look at the growth
Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody indicated for the treatment of several cancers, including melanoma, lung, head & neck, gastric, esophageal, and cervical among others. Keytruda sales have grown from $55 million in 2014 to $7.2 billion in 2018